Revenue
2022
2023
2024
2025
Brainstorm Cell Therapeutics Inc. (BCLI)
Price$1.05Cached quote
Net income
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $4.2M | $4.7M | $10.7M | $14.0M | $15.2M | $22.3M | $17.2M | $8.3M | $977,000 | $2.3M | $4.9M | $4.8M | $2.9M | $1.8M | $1.7M | $1.0M | — | — | — | — | — | — | — | — |
| Operating expenses | $10.0M | $11.7M | $21.4M | $24.8M | — | — | — | — | — | — | — | $7.4M | $5.0M | $3.5M | $3.9M | $2.6M | — | — | — | — | — | — | — | — |
| Operating income | −$10.0M | −$11.7M | −$21.4M | −$24.8M | −$24.5M | −$31.7M | −$23.0M | −$14.1M | −$5.0M | −$5.1M | −$8.5M | −$7.4M | −$4.9M | −$3.4M | −$3.9M | $2.4M | — | — | — | — | — | — | — | — |
| EBITDA | −$9.8M | −$11.5M | −$21.2M | −$24.5M | −$24.3M | −$31.5M | −$22.8M | −$14.0M | −$4.9M | −$5.0M | −$8.4M | −$7.3M | −$4.8M | −$3.3M | −$3.8M | — | — | — | — | — | — | — | — | — |
| Net income | −$10.3M | −$11.6M | −$17.2M | −$24.3M | −$24.5M | −$31.8M | −$23.3M | −$13.9M | −$5.0M | −$5.0M | −$8.5M | −$9.2M | −$4.9M | −$3.4M | −$3.9M | −$2.4M | −$1.8M | −$3.5M | −$6.2M | −$3.3M | −$18.8M | −$73,000 | −$47,000 | −$26,000 |
| Basic EPSper basic share | -$1.11 | -$2.31 | -$6.00 | -$147.76 | -$152.24 | -$239.55 | -$237.31 | -$156.72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$1.11 | -$2.31 | -$6.00 | -$147.76 | -$152.24 | -$239.55 | -$237.31 | -$156.72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Lebovits Chaim | 2M |
FRENKEL JACOB A | 243.78K |
Yablonka Uri | 218.46K |
ARBEL IRIT | 161.05K |
Patlis Alla | 144.35K |
Dagher Ibrahim B. | 79.52K |
HARTOUNIAN HARTOUN | 52K |
Lindborg Stacy | 48.23K |
Naor Nir | 31.47K |
Polverino Anthony J. | 25.73K |
Bairu Menghisteab | 24K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 1, 2024Form 4 | Lebovits ChaimPresident & CEO | BuyCommon Stock | 1.8K | $3.43 | $6.3K | 81.0K |
| Sep 30, 2024Form 4 | Lebovits ChaimPresident & CEO | BuyCommon Stock | 22.0K | $0.23 | $5.1K | 1.19M |
| Jul 19, 2024Form 4 | Dagher Ibrahim B.Chief Medical Officer | SellCommon Stock | 63.0K | $0.35 | $22.1K | 0 |
| May 28, 2024Form 4/A | Lebovits ChaimPresident & CEO | BuyCommon Stock | 15.0K | $0.52 | $7.8K | 1.16M |
| May 22, 2024Form 4/A | Lebovits ChaimPresident & CEO | BuyCommon Stock | 25.0K | $0.64 | $16.0K | 1.15M |